lystn

In this podcast, Ty J. Gluckman, MD, MHA, discusses the pivotal phase III FINEARTS-HF trial and how the treatment landscape is evolving for patients with heart failure (HF) with mildly reduced or preserved ejection fraction, including:

• The emerging role of mineralocorticoid receptor antagonists in HF care
• Finerenone’s efficacy in reducing composite cardiovascular death and worsening HF events 
• Why safety must be monitored, especially considering hyperkalemia risk
• Where HF guideline recommendations lack compared with the current evidence 

Presenter

Ty J. Gluckman, MD, MHA
Medical Director, Center for Cardiovascular Analytics, Research, and Data Science (CARDS)
Providence Heart Institute
Providence Health System
Portland, Oregon

Program page: 
https://bit.ly/448XcH0